At close: December 20 at 5:29:32 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
67,900.00
57,600.00
22,500.00
38,300.00
40,662.00
Cost of Revenue
207,500.00
204,500.00
142,600.00
96,600.00
185,171.00
Gross Profit
-139,600.00
-146,900.00
-120,100.00
-58,300.00
-144,509.00
Operating Expense
163,800.00
173,400.00
77,000.00
32,300.00
32,547.00
Operating Income
-303,400.00
-320,300.00
-197,100.00
-90,600.00
-177,056.00
Net Non Operating Interest Income Expense
-11,600.00
800.00
800.00
-100.00
162.00
Pretax Income
-319,200.00
-326,800.00
-193,800.00
-104,500.00
-178,024.00
Tax Provision
100.00
100.00
--
--
--
Net Income Common Stockholders
-319,300.00
-326,900.00
-193,800.00
-104,500.00
-178,024.00
Diluted NI Available to Com Stockholders
-319,300.00
-326,900.00
-193,800.00
-104,500.00
-178,024.00
Basic EPS
-1.10
-1.30
-1.00
-0.60
-2.39
Diluted EPS
-1.10
-1.30
-1.00
-0.60
-2.39
Basic Average Shares
291,489.03
256,752.28
194,238.21
179,906.46
73,448.93
Diluted Average Shares
296,039.58
260,011.48
194,238.21
179,906.46
73,448.93
Total Operating Income as Reported
-307,800.00
-324,800.00
-198,100.00
-105,700.00
-177,299.00
Total Expenses
371,300.00
377,900.00
219,600.00
128,900.00
217,718.00
Net Income from Continuing & Discontinued Operation
-319,300.00
-326,900.00
-193,800.00
-104,500.00
-178,024.00
Normalized Income
-319,617.60
-324,756.20
-193,800.00
-104,500.00
-178,024.00
Interest Income
12,500.00
4,900.00
900.00
100.00
163.00
Interest Expense
24,100.00
4,100.00
100.00
200.00
1.00
Net Interest Income
-11,600.00
800.00
800.00
-100.00
162.00
EBIT
-295,100.00
-322,700.00
-193,700.00
-104,300.00
-178,023.00
EBITDA
-295,100.00
-319,100.00
-191,000.00
-101,800.00
-177,628.00
Reconciled Cost of Revenue
207,500.00
204,500.00
142,600.00
96,600.00
185,171.00
Reconciled Depreciation
--
3,600.00
2,700.00
2,500.00
395.00
Net Income from Continuing Operation Net Minority Interest
-319,300.00
-326,900.00
-193,800.00
-104,500.00
-178,024.00
Total Unusual Items Excluding Goodwill
400.00
-2,700.00
--
--
--
Total Unusual Items
400.00
-2,700.00
--
--
--
Normalized EBITDA
-295,500.00
-316,400.00
-191,000.00
-101,800.00
-177,628.00
Tax Rate for Calcs
0.00
0.00
--
--
--
Tax Effect of Unusual Items
82.40
-556.20
--
--
--
12/31/2020 - 4/7/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
XBRANE.ST Xbrane Biopharma AB (publ)
0.1560
-4.29%
VICO.ST Vicore Pharma Holding AB (publ)
7.86
+2.75%
ISOFOL.ST Isofol Medical AB (publ)
2.4050
-3.80%
ONCO.ST Oncopeptides AB (publ)
1.5080
-1.69%
BIOVIC-B.ST Biovica International AB (publ)
1.7380
+8.63%
ACE.ST Ascelia Pharma AB (publ)
3.0000
-0.33%
HNSA.ST Hansa Biopharma AB (publ)
38.88
+6.11%
MVIR.ST Medivir AB (publ)
2.7600
-1.08%
AELIS.PA Aelis Farma SA
2.0800
0.00%
IRLAB-A.ST IRLAB Therapeutics AB (publ)
11.10
+1.83%